Search

Displaying results 4471 - 4480 of 10000 in total
  1. Drug

    Monofluorophosphate ion

    go.drugbank.com/drugs/DB02348
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Ethotoin

    go.drugbank.com/drugs/DB00754
    Approved

    Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin.

  3. Drug

    Setiptiline

    go.drugbank.com/drugs/DB09304
    Experimental

    In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.

  4. Drug

    Proxalutamide

    go.drugbank.com/drugs/DB16065
    Investigational

    Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).

  5. Drug

    Meclofenamic acid

    go.drugbank.com/drugs/DB00939
    ApprovedInvestigationalVet approved

    A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.

    Synonyms: N-(2,6-dichloro-m-tolyl)anthranilic acid, N-(2,6-dichloro-3-methylphenyl)anthranilic acid
  6. Drug

    Bardoxolone

    go.drugbank.com/drugs/DB12651
    Investigational

    In contrast, Bardoxolone in normal cells induces protective antioxidant/anti-inflammatory responses. … Bardoxolone has been used in trials studying the treatment of LYMPHOMA and Solid Tumors.

  7. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis.

  8. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. … It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.

  9. Drug

    Epinastine

    go.drugbank.com/drugs/DB00751
    Approved

    It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding

  10. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    It was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain).